Does Akers Biosciences Inc (NASDAQ:AKER) Have Gas After Even More Sellers Involved?

April 17, 2018 - By Migdalia James

Akers Biosciences, Inc. (NASDAQ:AKER) Logo

The stock of Akers Biosciences Inc (NASDAQ:AKER) registered an increase of 7.5% in short interest. AKER’s total short interest was 12.22M shares in April as published by FINRA. Its up 7.5% from 11.37 million shares, reported previously. With 13.11 million shares average volume, it will take short sellers 1 days to cover their AKER’s short positions.

The stock decreased 0.52% or $0.0028 during the last trading session, reaching $0.5397. About 3.88 million shares traded. Akers Biosciences, Inc. (NASDAQ:AKER) has declined 37.22% since April 17, 2017 and is downtrending. It has underperformed by 48.77% the S&P500.

Akers Biosciences, Inc., together with its subsidiaries, develops, makes, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and clients in the United States and internationally. The company has market cap of $51.79 million. The companyÂ’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. It currently has negative earnings. The Company’s marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘CheckÂ’, a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

WP Twitter Auto Publish Powered By :